Studies how pyrimidine and purine metabolism disorders affect the body
Compares test results from people with these disorders, family members, and healthy people.
Key facts
- Who runs it
- National Human Genome Research Institute (NHGRI)
- Where
- Bethesda, United StatesSee the site
- Trial code
- Registry title
- A Natural History Study Seeks to Understand the Clinical, Genomic, Pharmacological, Laboratory, and Dietary Determinates of Pyrimidine and Purine Metabolism Disorders
- Status
- Recruiting
- People taking part
- 999 people, planned
- Started
- 19 Dec 2023
- Expected to end
- 1 Jan 2099
- Type of study
- Observational, 3 groups
- Record updated
- 19 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for three groups: people with a purine or pyrimidine metabolism disorder, their unaffected family members, and healthy volunteers with no family history of these disorders.
- Age
- From 1 month of age and older, up to 100 years.
- Sex
- All sexes can join.
- Disease stage
- People with a known purine or pyrimidine metabolism disorder (DPPM), shown by medical history, lab tests, biochemical tests and/or gene tests. Family members must be unaffected by blood or marriage relatives of an enrolled person.
- Biomarker or test result
- For people with the disorder: lab, biochemical or gene findings consistent with a DPPM, for example harmful variants in genes of purine and pyrimidine pathways.
Main reasons for not taking part
- Unrelated healthy volunteers who have an intellectual disability from another cause and cannot consent without a guardian
- Other conditions that could interfere with reading the study results
- Pregnant unaffected family members and pregnant healthy volunteers
- No regular clinical care team outside of NIH
The registry criteria, word for word
Show all 21 criteriaShow less
Who cannot take part
- Individuals without a routine clinical care team outside of the NIH cannot enroll in this study. We will ask the participants for the name of clinical care team prior to enrollment
- Intercurrent or chronic conditions which in the opinion of the investigators, can then interfere with the interpretation of research studies (e.g. ongoing cancer treatment resulting in bone marrow suppression in a patient with DPPM also presenting with bone marrow suppression)
- Individuals meeting the following exclusion criteria are not eligible for the study:
- Unrelated volunteers who are unaffected with DPPM but have intellectual disability due to other causes, such that they cannot provide informed consent without a guardian/LAR, will not be enrolled in this study. Affected individuals and family member(s) of individuals with DPPM can participate in the study when appropriate informed consent is obtained (with aide of parents/guardian/LAR/bioethics review when necessary)
- Pregnant participants as unaffected family members or as unrelated healthy volunteers are not able to join the protocol during the pregnancy
Other criteria
- INCLUSION CRITERIA:; There are three populations that will be included in this study: subjects with known DPPM, family members of study subjects, and healthy controls; In order to be eligible to participate in this study as a subject with a known DPPM an individual must meet all following criteria:
- At least one month of age; A medical history that, based on the preponderance of clinical, laboratory, biochemical, and/or genomic evidence is consistent with DPPMs; Clinical findings that can be used to suspect disorders of purine and pyrimidine metabolism will include, but not be limited to the presence of congenital malformations, neurological, behavioral, immunological, rheumatological, hematological, renal involvement; gout; and recurrent rhabdomyolysis in one or more family members; Laboratory findings may include but not limited to elevated CPK (recurrent rhabdomyolysis); neutropenia, lymphopenia, anemia, thrombocytopenia; and immunodeficiency; Biochemical evidence may encompass but not limited to persistent laboratory abnormalities in blood and urinary urate (a terminal product of purine degradation); blood and urinary beta-alanine (a terminal product of pyrimidine degradation); characteristic findings on plasma amino acid profiles (elevated plasma aspartate and glycine); elevated orotic acid on the urine organic acid assay; presence of urate crystals in urine; abnormal findings on the purine and pyrimidine panels (e.g. plasma and urine purines \& pyrimidines biochemical panels at Mayo, PUPYP and PUPYU); Genomic evidence may include the presence of pathogenic and likely pathogenic variants in genes known or plausibly linked to the pathways of the de novo synthesis, degradation, and salvage of purines \& pyrimidines. Participants with variants of unknown significance in the said genes may be invited to participate in the protocol, if they have clinical, laboratory and biochemical evidence consistent with DPPMs
- Have a primary metabolic or genetic physician, or primary care provider; and
- Ability of the subject, parent/s (in the case of children), or a Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document; In order to be eligible to participate in this study as an unaffected family member of a subject with known DPPM, an individual must meet all the following criteria:
- At least one month of age
- Relationship either by blood or marriage, to an individual enrolled or about to be enrolled in the study with known DPPM
- Likelihood, in the expert opinion of the study team, that analysis of a sample from the individual would advance genetic or functional analysis of the affected relative s possible condition; and
- Ability of the subject, parent/s (in the case of children), or an LAR to understand and the willingness to sign a written informed consent document
- If during the consenting/assenting procedure, review of medical and family history and physical exam, clinical suspicion arises that a family member has symptoms of DPPMs, additional review and/or studies may be recommended to clarify the clinical status
- Participants must have a routine clinical care team outside of NIH to enroll in this study; In order to be eligible to participate in this study as an unrelated healthy volunteer, an individual must meet all the following criteria:
- No personal or family history of DPPMs
- At least one month old
- No symptoms of DPPMs
- Likelihood, in the expert opinion of the study team, that a sample from the individual would advance the functional analysis of the DPPM under study
- And ability of the subject, parent/s (in the case of children), or an LAR to understand and the willingness to sign a written informed consent document
- Participants must have a routine clinical care team outside of NIH to enroll in this study
Where in United States
- National Institutes of Health Clinical CenterBethesda, United StatesContact: Shannon HainesTaking people
About the trial
What the trial wants to find out
Background:
Read full original descriptionShow less
Pyrimidine and purine metabolism disorders (DPPMs) affect how the body metabolizes chemicals called pyrimidines and purines. DPPMs can cause dysfunctions throughout the body, especially in the brain, blood, kidneys, and immune system. People with DPPMs might have no symptoms, mild symptoms, or they may have severe, chronic symptoms, that can be fatal. DPPMs are not well understood, and researchers want to learn more about what causes them and how to treat them.
Objective:
To learn more about factors that affect DPPMs by comparing test results from affected, uaffected family members, and healthy people.
Eligibility:
Three types of participants are needed: people aged 1 month and older with DPPMs; their family members who do not have DPPMs; and healthy volunteers.
Design:
Participants with DPPMs will come to the clinic once a year; some may be asked to come more often. At each visit, all affected participants will have a physical exam and give samples of blood, urine, saliva, and stool. Depending on their symptoms, they may also have other procedures, such as:
Swabs of their skin and inside the mouth.
Tests of their heart, kidney, brain, and nerve function.
Questionnaires about what they eat.
Dental exams, and exams of their hearing and vision.
Tests of their learning ability.
Monitoring of their physical activity.
Imaging scans.
Photographs of their face and body.
These tests may be spread over up to 7 days. Affected participants may remain in the study indefinitely if they wish to.
Healthy volunteers and family members will have 1 study visit. They will have a physical exam and may be asked to give blood, urine, saliva, and stool samples.
The 3 groups in the trial
- Family Member of a subject with known or suspected DPPM
1\. At least one month of age;2. Relationship either by blood or marriage, to an individual enrolled or about to be enrolled in the study with known or suspected DPPM;3. Likelihood, in the expert opinion of the study team, that analysis of a sample from the individual would advance genetic or functional analysis of the affected relative s possiblecondition; and4. Ability of the subject, parent/s (in the case of children), or an LAR to understand and the willingness to sign a written informed consent document.5. If during the consenting/assenting procedure, clinical suspicion arises that a family member has symptoms of the diagnosed DPPMs, additional review and/or studies may be requested to clarify the clinical status before enrolling a family member as an unaffected participant.
- Healthy Volunteers
1\. No personal or family history of DPPMs;2. At least one month old;3. No symptoms of DPPMs;4. Likelihood, in the expert opinion of the study team, that a sample from the individual would advance the functional analysis of the DPPM under study; 5. And ability of the subject, parent/s (in the case of children), or an LAR to understand and the willingness to sign a written informed consent document.
- Subjects with known or suspected or uncharacterized DPPMs
1\. Regardless of gender, at least one month of age;2. A medical history that, in the expert opinion of the study team, is consistent with the DPPM; 3. Have a primary metabolic or genetic physician, or primary care provider; and 4. Ability of the subject, parent/s (in the case of children), or a Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Prospective Study of the Clinical, Genomic, Pharmacological, Laboratory, and Dietary Determinates of Pyrimidine and Purine Metabolism Disorders
- Plain-language title
- Studies how pyrimidine and purine metabolism disorders affect the bodyGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 19 August 2026